Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
COVID-19 severity is associated with the risk of gastrointestinal bleeding.
Hibiya S, Fujii T, Fujii T, Suzuki S, Kondo M, Ooka S, Furumoto Y, Azuma S, Tanaka K, Kurata H, Tanaka S, Kurosaki M, Nagayama K, Kusano F, Iizuka Y, Kawamura T, Ikemiyagi H, Sakita S, Yauchi T, Watanabe H, Kawamoto A, Matsuyama Y, Ohtsuka K, Okamoto R. Hibiya S, et al. Among authors: azuma s. BMJ Open Gastroenterol. 2023 Nov;10(1):e001199. doi: 10.1136/bmjgast-2023-001199. BMJ Open Gastroenterol. 2023. PMID: 37963649 Free PMC article.
Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
Nakagawa M, Nawa N, Takeichi E, Shimizu T, Tsuchiya J, Sato A, Miyoshi M, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Fujiwara T, Watanabe M, Tanaka Y, Asahina Y; Ochanomizu Liver Conference Study Group. Nakagawa M, et al. Among authors: azuma s. J Gastroenterol. 2020 Oct;55(10):990-999. doi: 10.1007/s00535-020-01715-6. Epub 2020 Aug 8. J Gastroenterol. 2020. PMID: 32770465
Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4-sclerosing cholangitis: Based on a Japanese nationwide study.
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, Takikawa H, Unno M, Kawa S, Masamune A, Nakamura S, Okazaki K; Collaborators. Kubota K, et al. J Gastroenterol Hepatol. 2023 Apr;38(4):556-564. doi: 10.1111/jgh.16066. Epub 2023 Jan 10. J Gastroenterol Hepatol. 2023. PMID: 36403136
Anticoagulation against portal vein thrombosis reduces mortality and liver cirrhosis-related complications: A propensity score-matched study.
Sato A, Watanabe S, Iseki M, Yamada Y, Kobayashi R, Furuya M, Arai K, Ohshina E, Tashiro Y, Nozaka T, Matsuoka M, Yauchi M, Kobayashi K, Matsumoto T, Furumoto Y, Asano T, Azuma S. Sato A, et al. Among authors: azuma s. Hepatol Res. 2023 Nov;53(11):1096-1104. doi: 10.1111/hepr.13942. Epub 2023 Jul 22. Hepatol Res. 2023. PMID: 37435880
Analysis of prognosis and background liver disease in non-advanced hepatocellular carcinoma in two decades.
Kaneko S, Asahina Y, Murakawa M, Azuma S, Inada K, Mochida T, Watakabe K, Shimizu T, Tsuchiya J, Miyoshi M, Kawai-Kitahata F, Nitta S, Takahashi M, Fujioka T, Kishino M, Anzai T, Kakinuma S, Nakagawa M, Okamoto R. Kaneko S, et al. Among authors: azuma s. PLoS One. 2024 Mar 7;19(3):e0297882. doi: 10.1371/journal.pone.0297882. eCollection 2024. PLoS One. 2024. PMID: 38452155 Free PMC article.
High serum gamma-glutamyltransferase level after hepatitis C virus elimination is a risk factor for the development of hepatocellular carcinoma.
Murakawa M, Nakagawa M, Nishimura H, Kaneko S, Miyoshi M, Kawai-Kitahata F, Nitta S, Tsuchiya J, Shimizu T, Watakabe K, Mochida T, Inada K, Iizuka Y, Sakai H, Sakurai Y, Sato A, Azuma S, Kawamura T, Maeyashiki C, Kurosaki M, Kusano F, Watanabe H, Kurata H, Karakama Y, Fujiwara T, Nagata Y, Tanaka T, Kakinuma S, Okamoto R, Asahina Y. Murakawa M, et al. Among authors: azuma s. Hepatol Res. 2024 Jul 29. doi: 10.1111/hepr.14094. Online ahead of print. Hepatol Res. 2024. PMID: 39073391
Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M. Nishimura-Sakurai Y, et al. Among authors: azuma s. J Gastroenterol. 2010 May;45(5):523-36. doi: 10.1007/s00535-009-0162-3. Epub 2009 Dec 12. J Gastroenterol. 2010. PMID: 20012654
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection.
Nakagawa M, Sakamoto N, Ueyama M, Mogushi K, Nagaie S, Itsui Y, Azuma S, Kakinuma S, Tanaka H, Enomoto N, Watanabe M. Nakagawa M, et al. Among authors: azuma s. J Gastroenterol. 2010 Jun;45(6):656-65. doi: 10.1007/s00535-009-0195-7. Epub 2010 Jan 30. J Gastroenterol. 2010. PMID: 20112032
354 results